all report title image
  • Published On : Aug 2022
  • Code : CMI2399
  • Industry : Pharmaceutical
  • Pages : 173
  • Formats :
Ingographics Image

Kidney cancer or renal carcinoma affects kidney cells to grow out of control and restrict the function of normal cells. Several risk factors associated with kidney cancer include smoking, obesity, workplace exposures substances such as cadmium, some herbicides, and organic solvents, particularly trichloroethylene, high blood pressure, advanced kidney disease, certain medicines, and genetic and hereditary risk factors. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure of these risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period. According to American Cancer Society, January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.

Market Dynamics

Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.

Key features of the study:

  • This report provides an in-depth analysis of the global kidney cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global kidney cancer drugs market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Genentech, Inc.,  Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation:

  • Global Kidney Cancer Drugs Market, By Therapy:
    • Targeted Therapy
    • Immunotherapy
    • Chemotherapy
  • Global Kidney Cancer Drugs Market, By Pharmacological Class:
    • Angiogenesis Inhibitors
    • mTOR Inhibitors
    • Cytokines
    • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Global Kidney Cancer Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies
  • Global Kidney Cancer Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis International AG
    • Genentech, Inc.
    • Active Biotech AB
    • Amgen Inc.
    • Bayer AG
    • Cipla Limited
    • Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Exelixis, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Kidney Cancer Drugs Market, By Therapy:
    • Targeted Therapy
    • Immunotherapy
    • Chemotherapy
  • Global Kidney Cancer Drugs Market, By Pharmacological Class:
    • Angiogenesis Inhibitors
    • mTOR Inhibitors
    • Cytokines
    • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Global Kidney Cancer Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies
  • Global Kidney Cancer Drugs Market, By Region:
    • North America
      • By Therapy:
        • Targeted Therapy
        • Immunotherapy
        • Chemotherapy
      • By Pharmacological Class:
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
        • Cytokines
        • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Therapy:
        • Targeted Therapy
        • Immunotherapy
        • Chemotherapy
      • By Pharmacological Class:
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
        • Cytokines
        • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy:
        • Targeted Therapy
        • Immunotherapy
        • Chemotherapy
      • By Pharmacological Class:
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
        • Cytokines
        • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy:
        • Targeted Therapy
        • Immunotherapy
        • Chemotherapy
      • By Pharmacological Class:
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
        • Cytokines
        • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Therapy
        • Lubiprostone
        • Linaclotide 
        • Eluxadoline 
        • Rifaximin
        • Alosetron
        • Other
      • By Pharmacological Class
        • IBS-constipation
        • IBS-diarrhea
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy
        • Lubiprostone
        • Linaclotide 
        • Eluxadoline 
        • Rifaximin
        • Alosetron
        • Other
      • By Pharmacological Class
        • IBS-constipation
        • IBS-diarrhea
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo